https://stockwhiz.ai/news/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for--0f66476cStockwhizen2026-10-25T16:00:00.066ZOruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026https://stockwhiz.ai/news/ivonescimab-plus-chemotherapy-demonstrates-overall-survival-superiorit-2c2d5682Stockwhizen2026-10-25T15:52:00.099ZIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in Chinahttps://stockwhiz.ai/news/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demons-734a2a15Stockwhizen2026-10-25T13:45:00.035ZRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerhttps://stockwhiz.ai/news/arrivent-announces-initial-phase-1-data-for-cdh17-targeted-adc-arr-217-2f28205cStockwhizen2026-10-25T13:00:00.069ZArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026https://stockwhiz.ai/news/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-fo-4644fdc3Stockwhizen2026-10-25T12:11:03.092ZAmarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)https://stockwhiz.ai/news/agenus-reports-72-of-patients-with-locally-advanced-dmmr-colon-cancer--92e638f7Stockwhizen2026-10-25T11:00:00.157ZAgenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026https://stockwhiz.ai/news/genmab-announces-updated-follow-up-analyses-from-phase-2-study-of-peto-00722a2bStockwhizen2026-10-25T11:00:00.108ZGenmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancerhttps://stockwhiz.ai/news/novabridge-biosciences-reports-mature-phase-1b-data-at-esmo-2026-posit-2100a9fcStockwhizen2026-10-25T10:59:59.983ZNovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Developmenthttps://stockwhiz.ai/news/reg-genmab-announces-updated-follow-up-analyses-from-phase-2-study-of--2af3bbefStockwhizen2026-10-25T10:59:59.925ZREG-Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancerhttps://stockwhiz.ai/news/libtayo-cemiplimab-longer-term-data-show-increasing-and-clinically-mea-1f0ef50bStockwhizen2026-10-25T09:14:59.964ZLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)https://stockwhiz.ai/news/xencor-presents-phase-1-dose-selection-data-for-xmab819-a-potential-fi-057f3dfeStockwhizen2026-10-25T08:35:00.091ZXencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumorshttps://stockwhiz.ai/news/johnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-ca-697e2d28Stockwhizen2026-10-25T07:30:00.225ZJohnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ moleculehttps://stockwhiz.ai/news/new-data-on-lilly-x27-s-investigational-treatment-olomorasib-at-esmo-2-6346b1ffStockwhizen2026-10-25T07:30:00.027ZNew data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerhttps://stockwhiz.ai/news/biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-da-1fcc7824Stockwhizen2026-10-25T07:29:59.860ZBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapyhttps://stockwhiz.ai/news/borr-drilling-limited-prospector-5-rig-incident-5a806164Stockwhizen2026-10-25T06:08:39.160ZBorr Drilling Limited - Prospector 5 Rig Incidenthttps://stockwhiz.ai/news/climb-bio-presents-initial-prismn-phase-2-data-from-budoprutug-in-pmn--1dbd7428Stockwhizen2026-10-24T23:29:59.912ZClimb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026https://stockwhiz.ai/news/axon-announces-body-5-next-generation-camera-built-for-the-ai-era-8e7721baStockwhizen2026-10-24T17:00:00.043ZAxon Announces Body 5: Next-Generation Camera Built for the AI Erahttps://stockwhiz.ai/news/pfizer-x27-s-25-valent-pediatric-pneumococcal-conjugate-vaccine-candid-0fe5872bStockwhizen2026-10-24T15:18:00.145ZPfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026https://stockwhiz.ai/news/from-private-credit-to-fusion-power-new-to-the-street-show-777-premier-c8837552Stockwhizen2026-10-24T14:31:20.370ZFrom Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Televisionhttps://stockwhiz.ai/news/imdelltra-in-combination-with-imfinzi-reduced-risk-of-death-by-an-unpr-1bf87700Stockwhizen2026-10-24T14:30:00.036ZIMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERhttps://stockwhiz.ai/news/johnson-johnson-announces-erleada-apalutamide-treatment-before-and-aft-94c5dbdaStockwhizen2026-10-24T12:55:08.680ZJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerhttps://stockwhiz.ai/news/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-d-b2988ad6Stockwhizen2026-10-24T12:44:59.340ZParabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumorshttps://stockwhiz.ai/news/semtech-brings-5g-network-slicing-fips-140-3-to-iacp-2026-c8bc1ea0Stockwhizen2026-10-24T12:00:00.117ZSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026https://stockwhiz.ai/news/genmab-and-incyte-announce-clinical-trial-collaboration-in-metastatic--ad70d4c3Stockwhizen2026-10-24T11:01:00.145ZGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancerhttps://stockwhiz.ai/news/incyte-and-genmab-announce-clinical-trial-collaboration-in-metastatic--c9f57118Stockwhizen2026-10-24T11:00:00.091ZIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancerhttps://stockwhiz.ai/news/reg-genmab-and-incyte-announce-clinical-trial-collaboration-in-metasta-88e1c061Stockwhizen2026-10-24T11:00:00.063ZREG-Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancerhttps://stockwhiz.ai/news/investor-notification-penske-automotive-group-pag-investors-are-remind-a7654352Stockwhizen2026-10-24T09:46:18.869ZInvestor Notification: Penske Automotive Group ($PAG) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $212.00 per Share Take-Private Merger Dealhttps://stockwhiz.ai/news/investor-notification-personalis-inc-psnl-investors-are-reminded-to-co-4fa5cc6bStockwhizen2026-10-24T09:46:18.774ZInvestor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Dealhttps://stockwhiz.ai/news/beone-presents-compelling-data-in-hard-to-treat-liver-and-lung-cancers-0bf5ea86Stockwhizen2026-10-24T08:15:00.158ZBeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026https://stockwhiz.ai/news/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-pha-90548491Stockwhizen2026-10-24T08:15:00.151ZCelcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026https://stockwhiz.ai/news/compass-therapeutics-announces-publication-of-phase-2-3-companion-002--a94a6836Stockwhizen2026-10-24T08:15:00.116ZCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026https://stockwhiz.ai/news/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targetin-d04af20dStockwhizen2026-10-24T06:30:00.121ZZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026https://stockwhiz.ai/news/immatics-presents-clinical-activity-of-ima402-prame-bispecific-and-ima-1ca7a1fbStockwhizen2026-10-24T06:30:00.065ZImmatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meetinghttps://stockwhiz.ai/news/lilly-presents-first-clinical-data-in-platinum-sensitive-ovarian-cance-9a3afa8dStockwhizen2026-10-24T06:30:00.034ZLilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026https://stockwhiz.ai/news/robot-consulting-announces-receipt-of-nasdaq-delisting-determination-a-dc7d4226Stockwhizen2026-10-24T04:00:01.293ZRobot Consulting Announces Receipt of Nasdaq Delisting Determination and Request to Appeal such Determination Before a Hearings Panelhttps://stockwhiz.ai/news/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-s-cc93d411Stockwhizen2026-10-24T01:26:44.316ZLunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Developmenthttps://stockwhiz.ai/news/rxsight-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-r-4a6a0ffeStockwhizen2026-10-24T00:00:00.093ZRxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Ruleshttps://stockwhiz.ai/news/us-metro-bancorp-announces-third-quarter-2026-results-9d47b96bStockwhizen2026-10-23T23:59:00.105ZUS Metro Bancorp Announces Third Quarter 2026 Resultshttps://stockwhiz.ai/news/travere-presents-new-biomarker-data-at-asn-kidney-week-suggesting-fils-1eac16eaStockwhizen2026-10-23T23:20:00.095ZTravere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathyhttps://stockwhiz.ai/news/hawaiian-electric-industries-to-announce-third-quarter-2026-results-no-9ef63f9fStockwhizen2026-10-23T23:16:00.116ZHawaiian Electric Industries to Announce Third Quarter 2026 Results November 6https://stockwhiz.ai/news/club-offers-for-travel-enthusiasts-in-canada-48e4a504Stockwhizen2026-10-23T23:08:29.067ZClub Offers for Travel Enthusiasts in Canadahttps://stockwhiz.ai/news/principal-real-estate-income-fund-announces-changes-in-portfolio-manag-52cddf1fStockwhizen2026-10-23T22:45:00.081ZPrincipal Real Estate Income Fund Announces Changes in Portfolio Management